Výsledky vyhledávání - "Lisa J McGarry"

Akademický článek

Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.

Autor: Lisa J McGarry, Zahra Bhaiwala, Andrea Lopez, Conor Chandler, Christopher G Pelligra, Jaime L Rubin, Theodore G Liou

Publikováno v: PLoS ONE, Vol 18, Iss 4, p e0283479 (2023)

ObjectivesCystic fibrosis (CF) is a rare genetic disease characterized by life-shortening lung function decline. Ivacaftor, a CF transmembrane conductance regulator modulator (CFTRm), was approved in 2012 for people with CF with specific gene mutatio

Externí odkaz: https://doaj.org/article/f383c0ab1efb464592cb3b9aa2390bc9

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis

Autor: Christian Merlo, Teja Thorat, Lisa J. McGarry, Christina V. Scirica, Maral DerSarkissian, Catherine Nguyen, Yuqian M. Gu, Aruna Muthukumar, Joe Healy, Jaime L. Rubin, M. Alan Brookhart

Publikováno v: Pulmonary Therapy, Vol 10, Iss 4, Pp 483-494 (2024)

Abstract Introduction Ivacaftor (IVA) has been shown to change the trajectory of cystic fibrosis (CF) disease progression by slowing the rate of lung function decline in clinical studies. Long-term real-world data help to confirm the durability of th

Externí odkaz: https://doaj.org/article/87a5f56fc12f4e5c98c0384be3eeadd6

Zobrazit plný text záznamu

Akademický článek

Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission.

Autor: Lisa J McGarry, Girishanthy Krishnarajah, Gregory Hill, Cristina Masseria, Michelle Skornicki, Narin Pruttivarasin, Bhakti Arondekar, Julie Roiz, Stephen I Pelton, Milton C Weinstein

Publikováno v: PLoS ONE, Vol 9, Iss 1, p e72723 (2014)

OBJECTIVES: In February 2012, the Advisory Committee on Immunization Practices (ACIP) advised that all adults aged ≥65 years receive a single dose of reduced-antigen-content tetanus, diphtheria, and acellular pertussis (Tdap), expanding on a 2010 r

Externí odkaz: https://doaj.org/article/b4f7f56207d34530a247249f61a3dbdd

Zobrazit plný text záznamu

Akademický článek

Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly.

Autor: Lisa J McGarry, Girishanthy Krishnarajah, Gregory Hill, Michelle Skornicki, Narin Pruttivarasin, Cristina Masseria, Bhakti Arondekar, Stephen I Pelton, Milton C Weinstein

Publikováno v: PLoS ONE, Vol 8, Iss 9, p e67260 (2013)

OBJECTIVES: Health benefits and costs of combined reduced-antigen-content tetanus, diphtheria, and pertussis (Tdap) immunization among adults ≥65 years have not been evaluated. In February 2012, the Advisory Committee on Immunization Practices (ACI

Externí odkaz: https://doaj.org/article/3d21d512d9d54d2890f1435092f3e59f

Zobrazit plný text záznamu

The Cystic Fibrosis Impact Questionnaire: qualitative development and cognitive evaluation of a new patient-reported outcome instrument to assess the life impacts of cystic fibrosis

Autor: Mona L. Martin, Paul Hodgkins, Lisa J McGarry, E. Suthoff, K.P. McCarrier, M. Hassan

Publikováno v: Journal of Patient-Reported Outcomes, Vol 4, Iss 1, Pp 1-11 (2020)
Journal of Patient-Reported Outcomes

Background Patients with cystic fibrosis (CF) experience significant disease burden, including progressive pulmonary decline and reduced survival. This multicenter qualitative study was conducted to develop a new patient-reported outcome (PRO) measur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a0b2988f2f0cda3c1d6d8fcf5a9cf95
http://link.springer.com/article/10.1186/s41687-020-00199-5

Zobrazit plný text záznamu

EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS

Autor: Tim Lee, Gregory S. Sawicki, Josje Altenburg, Stefanie J. Millar, Jessica Morlando Geiger, Mark T. Jennings, Yiyue Lou, Lisa J. McGarry, Kate Van Brunt, Rachel W. Linnemann

Publikováno v: Lee, T, Sawicki, G S, Altenburg, J, Millar, S J, Geiger, J M, Jennings, M T, Lou, Y, McGarry, L J, van Brunt, K & Linnemann, R W 2022, ' EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS ', Journal of Cystic Fibrosis . https://doi.org/10.1016/j.jcf.2022.12.009
Journal of cystic fibrosis. Elsevier
Journal of Cystic Fibrosis. Elsevier

Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious in people with cystic fibrosis (CF) with ? 1 F508del-CFTR allele in Phase 3 clinical trials. ELX/TEZ/IVA treatment led to improved lung function, with increases in pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56a1d99eddd8699a4243713c1a1787c1
https://doi.org/10.1016/j.jcf.2022.12.009

Zobrazit plný text záznamu

Development of the CFQ-R-8D: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised

Autor: Sarah, Acaster, Clara, Mukuria, Donna, Rowen, John E, Brazier, Claire E, Wainwright, Bradley S, Quon, Jamie, Duckers, Alexandra L, Quittner, Yiyue, Lou, Patrick, Sosnay, Lisa J, McGarry

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cystic fibrosis (CF) limits survival and negatively affects health-related quality of life (HRQOL). Cost-effectiveness analysis (CEA) may be used to make reimbursement decisions for new CF treatments; however, generic utility measures used in CEA, su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::72d50bc3024311f8dc409d304d322641
https://pubmed.ncbi.nlm.nih.gov/36509366

Zobrazit plný text záznamu

Healthcare resource utilization and costs among children with cystic fibrosis in the United States

Autor: Brendan Limone, Machaon Bonafede, Jaime L. Rubin, Michael W. Konstan, Krutika Jariwala-Parikh, Teja Thorat, Lisa J McGarry

Publikováno v: Pediatric Pulmonology

Background Adverse health impacts of cystic fibrosis (CF) can be present in children before respiratory complications are observed. Children with CF show progressive health decline, with increasing lung function decline in adolescence. This study aim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b811f14eb2287bd0c92965c31abab208
https://pubmed.ncbi.nlm.nih.gov/34138523

Zobrazit plný text záznamu

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States

Autor: Lisa J McGarry, Michael W. Konstan, Brendan Limone, Keval Chandarana, Krutika Jariwala-Parikh, Teja Thorat, Machaon Bonafede

Publikováno v: Pulmonary Therapy

Introduction Ivacaftor was first approved in 2012 for the treatment of a select population of individuals with cystic fibrosis (CF), a rare, life-shortening genetic disease. Reductions in healthcare resource utilization (HCRU) associated with ivacaft

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae6809d724430c254fb96e67c3464e4d
https://doi.org/10.1007/s41030-021-00154-9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání